Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma

Published:2011-11 Issue:11 Volume:35 Page:1457-1463
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Drain Stephen,Flannely Louise,Drake Mary B.,Kettle Paul,Orr Nick,Bjourson Anthony J.,Catherwood Mark A.,Alexander H. Denis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Cell biological mechanisms of multidrug resistance in tumors;Sanford;Proc Natl Acad Sci,1994

2. ABC transporters in cancer: more than just drug efflux pumps;Fletcher;Nat Rev Cancer,2010

3. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors;Coley;Methods Mol Biol,2010

4. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia;Ma;J Biomed Nanotechnol,2009

5. The multidrug resistance protein family;Borst;Biochim Biophys Acta,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDR1 rs1045642 Variant Is Linked with Lower Expression and Extends Overall Survival of Multiple Myeloma: A Hospital-Based Case-Control Study;Russian Journal of Genetics;2023-11

2. The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma;Journal of Clinical Medicine;2021-11-13

3. Effect of ABC transporter expression and mutational status on survival rates of cancer patients;Biomedicine & Pharmacotherapy;2020-11

4. Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients;Scientific Reports;2018-10-19

5. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial;Cancer Chemotherapy and Pharmacology;2017-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3